Literature DB >> 11694699

Insulin lispro lowers postprandial glucose in prepubertal children with diabetes.

L C Deeb1, J H Holcombe, R Brunelle, S Zalani, S Brink, M Jenner, H Kitson, K Perlman, M Spencer.   

Abstract

OBJECTIVE: This study compared the glucose-lowering effect of insulin lispro, given before or after meals, with regular human insulin given before meals in prepubertal children with diabetes. RESEARCH DESIGN AND METHODS: A 3-way crossover, open-label study involving 61 prepubertal children (ages 2.9-11.4 years) with type 1 diabetes. The children were randomly assigned to receive regular human insulin 30 to 45 minutes before meals, insulin lispro within 15 minutes before or immediately after meals, combined with basal insulin. Each treatment lasted 3 months. Hemoglobin A(1c) levels and home glucose monitoring profiles were measured at the end of each treatment period.
RESULTS: Treatment with insulin lispro before breakfast resulted in lower 2-hour postprandial glucose values than regular human insulin (11.7 +/- 4.4 mmol/L vs 15.0 +/- 5.4 mmol/L). Similarly, insulin lispro given before dinner resulted in lower blood glucose values 2 hours postprandially (8.8 +/- 5.0 mmol/L vs 10.8 +/- 5.4 mmol/L) than regular human insulin. When insulin lispro was administered after meals, the 2-hour glucose levels were between those seen with either insulin lispro or regular human insulin given before meals. The number and types of adverse events, the rates of hypoglycemia, and the HbA(1c) levels did not differ among the 3 therapies.
CONCLUSIONS: In prepubertal children, insulin lispro given before meals is safe and significantly lowers postprandial glucose levels after breakfast and dinner compared with regular human insulin, and insulin lispro given after the meal provides similar benefits as regular human insulin before the meal.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11694699     DOI: 10.1542/peds.108.5.1175

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  8 in total

1.  Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy.

Authors:  A Siebenhofer; J Plank; A Berghold; K Horvath; P T Sawicki; P Beck; T R Pieber
Journal:  Diabetologia       Date:  2004-11-25       Impact factor: 10.122

Review 2.  Insulin lispro: a pharmacoeconomic review of its use in diabetes mellitus.

Authors:  Christopher J Dunn; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

3.  Rapid-Acting Insulin Analogues for the Treatment of Diabetes Mellitus: Meta-analyses of Clinical Outcomes.

Authors: 
Journal:  CADTH Technol Overv       Date:  2010-03-01

Review 4.  Insulin lispro: a review of its use in the management of diabetes mellitus.

Authors:  Dene Simpson; Paul L McCormack; Gillian M Keating; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis.

Authors:  Sumeet R Singh; Fida Ahmad; Avtar Lal; Changhua Yu; Zemin Bai; Heather Bennett
Journal:  CMAJ       Date:  2009-02-17       Impact factor: 8.262

6.  Timing of Meal Insulin and Its Relation to Adherence to Therapy in Type 1 Diabetes.

Authors:  Karishma A Datye; Claire T Boyle; Jill Simmons; Daniel J Moore; Sarah S Jaser; Nicole Sheanon; Julie M Kittelsrud; Stephanie E Woerner; Kellee M Miller
Journal:  J Diabetes Sci Technol       Date:  2017-09-12

Review 7.  Efficacy and Safety of Rapid-Acting Insulin Analogs in Special Populations with Type 1 Diabetes or Gestational Diabetes: Systematic Review and Meta-Analysis.

Authors:  Kirsten Nørgaard; Nithya Sukumar; Snorri B Rafnsson; Ponnusamy Saravanan
Journal:  Diabetes Ther       Date:  2018-04-05       Impact factor: 2.945

8.  Impact of carbohydrate counting on glycemic control in children with type 1 diabetes.

Authors:  Sanjeev N Mehta; Nicolle Quinn; Lisa K Volkening; Lori M B Laffel
Journal:  Diabetes Care       Date:  2009-02-24       Impact factor: 19.112

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.